AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20935397
Drug: Oral doxophylline
RxNorm normalized name: proxyphylline
DrugBank: Proxyphylline (DB13449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxophylline (400 mg/day)
Trial: 20935397
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (400 mcg)
Trial: 1531285
Drug: Foscarnet (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet (40 mg/kg every 8 or 12 hours)
Trial: 1531285
Drug: Acyclovir maintenance
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir maintenance following foscarnet induction therapy
Trial: 31423712
Drug: High-intensity care
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity care (up-titration of oral HF medications including beta-blockers, ACE inhibitors or ARBs, and MRAs)
Trial: 29417902
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (5 × 10^7 haMSCs)
Trial: 29417902
Drug: Mid-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-dose group (2 × 10^7 haMSCs)
Trial: 29417902
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (1 × 10^7 haMSCs)
Trial: 18538110
Drug: Depot antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot antipsychotic drugs (DA)
Trial: 11252212
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (n=49) received meal plans, recipes, and nutritional information during monthly group office sessions
Trial: 9416938
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg 2 times daily)
Trial: 9416938
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg 2 times daily) + Aspirin (325 mg/day)
Trial: 9416938
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg/day) + Aspirin (325 mg/day)
Trial: 8295813
Drug: Clarithromycin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 7.5 mg/kg twice daily, maximum 500 mg twice daily (n = 161)
Trial: 8295813
Drug: Amoxicillin/clavulanate 13.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate 13.3 mg/kg three times daily, maximum 500 mg three times daily (n = 177)
Trial: 3091459
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of Fragmin (anti-FXa: 0.2-0.3 U/ml)
Trial: 11443185
Drug: Canrenoate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canrenoate (200 mg as iv bolus at 2000 h, followed by 200 mg infused in 500 mL saline over 4 h up to 2400 h)
Trial: 11443185
Drug: Placebo (saline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline, 1.0 mL as iv bolus at 2000 h, followed by 500 mL over 4 h up to 2400 h)
Trial: 25258407
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg/day for 14 days
Trial: 18793544
Drug: Cockroft and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cockroft and Gault (C&G)
Trial: 16041739
Drug: Atrisin (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrisin (three capsules/day)
Trial: 2262649
Drug: Intranasal budesonide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal budesonide, 400 micrograms two times a day
Trial: 30706457
Drug: 0.05% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% tretinoin cream (TRE) every other night
Trial: 30706457
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day oral isotretinoin (ISO)
Trial: 30121097
Drug: Talking with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talking with Teens about Traffic Safety Program (treatment group)
Trial: 20473056
Drug: 10-mg intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg intramuscular olanzapine
Trial: 20473056
Drug: 10-mg orally
RxNorm normalized name: rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-mg orally disintegrating olanzapine tablets
Trial: 20473056
Drug: 3-mg oral
RxNorm normalized name: glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-mg oral risperidone solution
Trial: 20473056
Drug: 7.5-mg intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5-mg intramuscular haloperidol
Trial: 17852863
Drug: NO-generating solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO-generating solution
Trial: 17852863
Drug: Control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solution (hydrochloric acid pH 1.0)
Trial: 17852863
Drug: Nitrous acid
RxNorm normalized name: Nitrous acid
DrugBank: Nitrous acid (DB09112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrous acid solution
Trial: 12649048
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dietary advice and exercise
Trial: 1479709
Drug: rEPO administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rEPO administered twice a week (group A)
Trial: 1479709
Drug: rEPO administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rEPO administered once a week (group B)
Trial: 6463067
Drug: Midazolam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1 to 0.15 mg/kg) with suxamethonium (1 mg/kg)
Trial: 6463067
Drug: Midazolam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1 to 0.15 mg/kg) with pancuronium (0.075 mg/kg)
Trial: 30513095
Drug: CEE plus
RxNorm normalized name: Ecee Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE plus 2.5 mg/d of medroxyprogesterone acetate (MPA)
Trial: 25133471
Drug: Oxandrolone (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone (0.03 mg/kg per day or 0.06 mg/kg per day)
Trial: 11834851
Drug: Vehicle (steroid-free)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (steroid-free) with wet-wrap dressings
Trial: 2525897
Drug: Transdermal clonidine
RxNorm normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal clonidine and Placebo
Trial: 30677506
Drug: roniciclib plus
RxNorm normalized name: Roniciclib
DrugBank: Roniciclib (DB12974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roniciclib plus chemotherapy
Trial: 29136094
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (800 mg docosahexanoic acid and up to 225 mg eicosapentanoic acid)
Trial: 26508094
Drug: TMZ/ABT‐888 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMZ/ABT‐888 (40 mg BID ABT‐888 with 75 mg/m² TMZ for 21 days)
Trial: 26508094
Drug: TMZ/ABT‐888 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMZ/ABT‐888 (40 mg BID ABT‐888 with 150-200 mg/m² TMZ for 5 days)
Trial: 24821941
Drug: XSPI, central
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XSPI, central systolic blood pressure, central augmentation pressure, central pulse pressure, integral of reservoir pressure
Trial: 24821941
Drug: XSPI, augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XSPI, augmentation pressure, central pulse pressure
Trial: 16287051
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy and routine care
Trial: 12058514
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy training
Trial: 9865017
Drug: Metopress-retard 100
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metopress-retard 100 mg taken at 8 a.m.
Trial: 9865017
Drug: Metopress-retard 100
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metopress-retard 100 mg taken at 8 p.m.
Trial: 7783666
Drug: Sorbitol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol (2.5 to 20 g in iso-osmolar solutions)
Trial: 7783666
Drug: Sorbitol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol (20 g)
Trial: 7783666
Drug: Sorbitol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol (up to 10 g)
Trial: 2547300
Drug: Pea fiber
RxNorm normalized name: Pea fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pea fiber (PF) 15 g
Trial: 2547300
Drug: Control meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control meal (150 g ground beef, 50 g glucose, 20 g lactulose)
Trial: 24986094
Drug: Glycopyrronium (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium (400 µg, single inhaled supra-therapeutic dose)
Trial: 22818144
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg PD‐0299685 daily
Trial: 22818144
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg PD‐0299685 daily
Trial: 17334512
Drug: NCX 4016
RxNorm normalized name: NCX 701
DrugBank: NCX 701 (DB05409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCX 4016 (800 mg b.i.d.)
Trial: 17334512
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg o.d.)
Trial: 10030463
Drug: Zatebradine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zatebradine 10 mg i.v. (n = 24)
Trial: 23933066
Drug: Strength and
RxNorm normalized name: Excedrin Extra Strength and Excedrin Tension Headache KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength and endurance training performed twice a week (SE2, n=12)
Trial: 16884320
Drug: Febuxostat 10-240
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 10-240 mg
Trial: 10564141
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (NP) infusion (0.3-1.0 microgram.kg(‐1).min(‐1))
Trial: 8638581
Drug: Treatment without
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment without extraction
Trial: 1666275
Drug: All surgical
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All surgical treatments
Trial: 6339312
Drug: Furosemide (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (80 mg/day, increased to 160 mg/day if no response)
Trial: 6339312
Drug: Spironolactone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (150 mg/day, increased to 300 mg/day if no response)
Trial: 28825423
Drug: DMXB-A 150
RxNorm normalized name: DMXB-A
DrugBank: GTS-21 (DB05708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMXB-A 150 mg (extended-release formulation) administered four times daily for 1 month
Trial: 23689047
Drug: Oxygen-driven nebulization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen-driven nebulization (ODN) at 4-5 L/min
Trial: 23689047
Drug: Oxygen-driven nebulization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen-driven nebulization (ODN) at 6-7 L/min
Trial: 23689047
Drug: Oxygen-driven nebulization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen-driven nebulization (ODN) at 8-9 L/min
Trial: 21086650
Drug: Glucose-salt solutions
RxNorm normalized name: glucose Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-salt solutions
Trial: 12848774
Drug: Retigabine 200
RxNorm normalized name: retigabine 200 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retigabine 200 mg
Trial: 12848774
Drug: Retigabine 200
RxNorm normalized name: retigabine 200 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retigabine 200 mg every 8 h on day 32
Trial: 12848774
Drug: Phenobarbitone 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone 90 mg
Trial: 12848774
Drug: Phenobarbitone 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone 90 mg after retigabine administration
Trial: 10493336
Drug: 5-component acellular
RxNorm normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-component acellular pertussis vaccine
Trial: 8902922
Drug: Vigabatrin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (2 g daily)
Trial: 1988239
Drug: Magnesium hydroxide
RxNorm normalized name: Magnesium Hydroxide
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium hydroxide (850 mg) with glipizide (5 mg)
Trial: 1988239
Drug: Control (water)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (water) with glipizide (5 mg)
Trial: 6294732
Drug: Intramuscular sincalide
RxNorm normalized name: Sincalide
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular sincalide
Trial: 6294732
Drug: Intravenous sincalide
RxNorm normalized name: Sincalide
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous sincalide
Trial: 30108163
Drug: Glutamine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (5 g t.i.d.)
Trial: 28547078
Drug: 4% articaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% articaine with 1:100,000 adrenaline as buccal and lingual infiltration
Trial: 23979151
Drug: Various antibiotics
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various antibiotics tested (excluding imipenem)
Trial: 19682170
Drug: Isoproterenol (ISO)
RxNorm normalized name: isoproterenol sulfate Metered Dose Inhaler [Medihaler-Iso]
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoproterenol (ISO) administered in escalating doses of 5, 10, 15, and 20 microg/min
Trial: 18845996
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (DOX) 60 mg/m² every 3 weeks
Trial: 18845996
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) 50 mg/m² every 4 weeks
Trial: 8455319
Drug: Simultaneous infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous infusion of all substrates with bolus‐based intermittent infusions during 60 minutes six times per day (24 hours)
Trial: 8455319
Drug: Sequential infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential infusion of fat plus amino acids at a constant rate over 12 hours during daytime followed by glucose infusion at a constant rate for 12 hours during nighttime
Trial: 8455319
Drug: Simultaneous infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous infusion of all substrates at a constant rate over 24 hours
Trial: 3510410
Drug: Dexamethasone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (40 mg/m2 for doxorubicin, 95 mg/m2 for cis-platinum) administered intravenously 15 min prior to chemotherapy
Trial: 29758154
Drug: Oscillating-rotating electric
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oscillating-rotating electric rechargeable toothbrush (Oral-B® PRO 1000, D16U)
Trial: 26058585
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose theophylline (Uniphyllin MR 200 mg tablets)
Trial: 18155202
Drug: Pre-ART cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-ART cycle screening with saline infusion sonohysterography
Trial: 16580384
Drug: Intranasal E2/NET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal E2/NET (175 microg/275 microg) as a spray
Trial: 16580384
Drug: Oral E2/NETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E2/NETA (1 mg/0.5 mg) as a capsule
Trial: 9586788
Drug: Oral, semielemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, semielemental diet (SED)
Trial: 3041336
Drug: Widely available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Widely available topical preparation
Trial: 29843761
Drug: Electro-acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-acupuncture treatment for 10 days in addition to routine pharmacological treatment.
Trial: 29843761
Drug: Routine pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine pharmacological treatment alone (Control group).
Trial: 26232375
Drug: Romosozumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romosozumab (1 or 2 mg/kg Q2W or 2 or 3 mg/kg Q4W)
Trial: 21917894
Drug: Darunavir/ritonavir (DRV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir (DRV/r) monotherapy
Trial: 17046383
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia (no additional medication)
Trial: 17046383
Drug: Sublingual lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual lorazepam (0.5 to 1 mg, approximately 20 min preoperatively)
Trial: 17046383
Drug: Intravenous sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sedation (fentanyl and midazolam, doses from 50 to 125 microg of fentanyl and 1‐2 mg of midazolam)
Trial: 1546818
Drug: Ketotifen (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (0.8 mg for <14 kg, 1.2 mg for ≥14 kg)
Trial: 31517555
Drug: Kaempferia parviflora
RxNorm normalized name: Kaempferia galanga root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaempferia parviflora extract (KPE) - 5 tablets daily (150 mg KPFORCE™/tablet) for 4 weeks
Trial: 31517555
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 5 tablets daily for 4 weeks
Trial: 19918712
Drug: 0.5% Boswellic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% Boswellic acid cream
Trial: 19918712
Drug: Base cream
RxNorm normalized name: U-Base Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Base cream without Boswellic acid
Trial: 16000173
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (endoscopy into the sacral level without adhesiolysis, followed by injection of local anesthetic and steroid)
Trial: 12140473
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using methyl 5‐aminolevulinate cream 160 mg/g, 3 hours application time, and red light (75 J/cm(2))
Trial: 12140473
Drug: Cryotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy with liquid nitrogen spray
Trial: 12140473
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using methyl 5‐aminolevulinate
Trial: 7675960
Drug: Buprenorphine (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (2, 4, and 8 mg sl.)
Trial: 7675960
Drug: Methadone (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (15, 30, and 60 mg PO)
Trial: 25567367
Drug: ABT-639 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-639 (up to 170 mg single dose and up to 160 mg BID multiple doses)
Trial: 16933268
Drug: High-dose methyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methyl prednisolone (HDMP)
Trial: 11270019
Drug: Remifentanil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (1 microgram kg‐1 bolus followed by 0.1 microgram kg‐1 min‐1 infusion)
Trial: 11270019
Drug: Sufentanil (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (0.1 microgram kg‐1 bolus over 60 s followed by 0.01 microgram kg‐1 min‐1 infusion)
Trial: 3810050
Drug: Pivampicillin/pivmecillinam (PAPM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin/pivmecillinam (PAPM) 450 mg and 900 mg every 12 h until catheter removal (max 1 week)
Trial: 3810050
Drug: Cefotaxime (CFT)
DrugBank: Cefotaxime (DB00493)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefotaxime (CFT) 1 g daily parenterally
Trial: 30376893
Drug: TXA dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA dose A (15 mg/kg bolus dose over 20 min, followed by 2 mg/kg/hr infusion over 8 h)
Trial: 30376893
Drug: TXA dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA dose B (30 mg/kg bolus dose over 20 min, followed by 4 mg/kg/hr infusion over 8 h)